Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021
Open accessPublished version of a preprint
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Recently, Covid-19 vaccine effectiveness has decreased especially against mild disease due to emergence of the Delta variant and waning protection. In this register-based study among healthcare workers in Finland, the vaccine effectiveness of two-dose mRNA vaccine series against SARS-CoV-2 infection decreased from 82% (95% CI 79-85%) 14-90 days after vaccination to 53% (43-62%) after 6 months. Similar trend was observed for other series. Waning was not observed against Covid-19 hospitalization. These results facilitate decision-making of booster doses for healthcare workers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 1×
“Covid-19 vaccines have been highly efficacious [1, 2].”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · doi:10.1101/2021.07.28.21261159 · Cited by 1,640
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110345 · Cited by 1,640 · cited 4×
“The effect measure was VE, quantified as 1 minus the hazard ratio adjusted for age, sex, presence of medical conditions predis- *Series that include at least one vaccination with a Covid-19 vaccine other than Comirnaty, Spikevax and Vaxzevria or with a Covid-19 vaccine that was not properly recorded and could thus not…”
InfluentialProtection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034 · cited 1×
“We did not detect changes in VE following the emergence of Delta, indicating that the decrease in VE against infection is due to waning of vaccine-induced immunity, which has also been seen elsewhere [2,4,5,11,14].”
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
Skowronski, D. M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot, D., Prystajecky, N., Tyson, J. R., Gilca, R., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac290 · Cited by 155
Research works printed but not linked: 10
- Keehner, 2021, Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce, N Engl J Med., 385, 1330, 10.1056/NEJMc2112981 · DOI · Paper page
- Baum, 2021, Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalization among Finnish elderly and chronically ill – An interim analysis of a nationwide cohort study [Preprint], Infectious Diseases (except HIV/AIDS)
- Andrews, 2021, Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK [Preprint], Epidemiology
- Gram MA, Nielsen J, Schelde AB, Nielsen KF, Moustsen-Helms IR, Bjørkholt Sørensen AK, et al. Vaccine effectiveness when combining the ChAdOx1 vaccine as the first dose with an mRNA COVID-19 vaccine as the second dose [Preprint]. Epidemiology; 2021 Jul [cited 2021 Nov 1]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.07.26.21261130. · DOI
- Nordström, 2021, Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study, The Lancet Regional Health - Europe, 11, 100249, 10.1016/j.lanepe.2021.100249 · DOI · Paper page
- Pilishvili, 2021, Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel, N Engl J Med, 385, e90, 10.1056/NEJMoa2106599 · DOI · Paper page
- de Gier B, Andeweg S, Backer JA, RIVM COVID-19 surveillance and epidemiology team, Hahné SJM, van den Hof S, et al. Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands [Preprint]. Epidemiology; 2021 Oct [cited 2021 Nov 1]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.10.14.21264959. · doi:10.1101/2021.10.14.21264959
- Payne RP, Longet S, Austin JA, Skelly D, Dejnirattisai W, Adele S, et al. Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine. SSRN Journal [Preprint]. 2021 [cited 2021 Nov 1]; Available from: https://www.ssrn.com/abstract=3891065. · DOI
- Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Hallis B, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation in older people [Preprint]. Infectious Diseases (except HIV/AIDS); 2021 May [cited 2021 Nov 1]. Available from: http://medrxiv.org/lookup/doi/10.1101/2021.05.15.21257017. · DOI
- Baum, 2020, Cohort study design for estimating the effectiveness of seasonal influenza vaccines in real time based on register data: The Finnish example, Scand J Public Health. toukokuuta, 48, 316, 10.1177/1403494818808635 · DOI
Cited by
Zeng, B., Gao, L., Zhou, Q., Yu, K., & Sun, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02397-y · Cited by 275
Au, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139
(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43
(2022) · doi:10.1101/2022.03.29.22273086 · Cited by 4
Metadata
- Authors
- Poukka, E., Baum, U., Palmu, A. A., Lehtonen, T. O., Salo, H., Nohynek, H., & Leino, T.
- Venue
- Vaccine
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 40
- Issue
- 5
- Pages
- 701-705
- ISSN
- 0264-410X (ISSN-L)
- OpenAlex
- W4226212768
- Cited by
- 58
- References
- 10
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. https://app.cochat.ai/papers/10.1016/j.vaccine.2021.12.032
- The paper
- Poukka, E., Baum, U., Palmu, A. A., Lehtonen, T. O., Salo, H., Nohynek, H., & Leino, T. (2022). Cohort study of Covid-19 vaccine effectiveness among healthcare workers in Finland, December 2020 - October 2021. Vaccine. https://doi.org/10.1016/j.vaccine.2021.12.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.